Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Psoriasis 7 Lymphoma, Follicular 7 Bronchiolitis Obliterans Syndrome 7 Pruritus 5 Arthritis, Rheumatoid 3 Plaque, Amyloid 1 Myasthenia Gravis 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Extranodal NK-T-Cell 1 Glioblastoma 1 Cholangiocarcinoma 1 Arthritis, Psoriatic 1 Adenocarcinoma 1

Interventions

Temozolomide 393 Radiotherapy 196 Bevacizumab 156 Radiation 77 Magnetic Resonance Spectroscopy 68 Lomustine 47 Surgical Procedures, Operative 42 Carmustine 41 pembrolizumab 39 Irinotecan 38 Nivolumab 32 Specimen Handling 27 Carboplatin 27 Radiosurgery 24 Erlotinib Hydrochloride 24 Chemotherapy, Adjuvant 23 Radiotherapy, Intensity-Modulated 22 Drug Therapy 21 Cyclophosphamide 20 Aminolevulinic Acid 20 O(6)-benzylguanine 17 sargramostim 16 Radiotherapy, Conformal 15 temsirolimus 14 Granulocyte-Macrophage Colony-Stimulating Factor 14 Everolimus 14 Vorinostat 13 Sorafenib 13 poly ICLC 12 atezolizumab 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Glioblastoma × tofacitinib × Clear all

NCT05326464 2025-12-15

Tofacitinib in Recurrent GBM Patients

University of Texas Southwestern Medical Center

Phase 3 Active not recruiting

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡